Moving Stocks: Blueprint Medicines Corporation (NASDAQ:BPMC), EnerSys (NYSE:ENS), Agree Realty Corp. (NYSE:ADC), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Matson, Inc. (NYSE:MATX)

Cowen and Company restated their buy rating on shares of Blueprint Medicines Corporation (NASDAQ:BPMC) in a research note issued to investors on Monday. Blueprint Medicines Corporation (NASDAQ:BPMC) belongs to Healthcare sector. Its weekly performance is 3.96%. On last trading day company shares ended up $27.59. Blueprint Medicines Corporation (NASDAQ:BPMC) distance from 50-day simple moving average (SMA50) is -7.03%.

EnerSys (NYSE:ENS) announced its Board of Directors has declared a quarterly cash dividend of $0.175 per share of common stock payable on September 25, 2015 to holders of record as of September 11, 2015.EnerSys (NYSE:ENS) shares fell -9.74% in last trading session and ended the day at $55.50. ENS Gross Margin is 25.60% and its return on assets is 8.00%. EnerSys (NYSE:ENS) quarterly performance is -17.15%.

On 27 July, Agree Realty Corp. (NYSE:ADC) announced results for the quarter ended June 30, 2015. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Total rental revenue, which includes minimum rents and percentage rents, for the three months ended June 30, 2015 increased 35.0% to $16,113,000 compared with total rental revenue of $11,933,000 for the comparable period in 2014.On 06 August, Agree Realty Corp. (NYSE:ADC) shares fell -0.07% and was closed at $30.50. ADC EPS growth in last 5 year was -6.40%. Agree Realty Corp. (NYSE:ADC) year to date (YTD) performance is 1.05%.

On 5 August, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced financial results for the quarter and six months ended June 30, 2015, and provided updates on its clinical development programs. The net loss for the second quarter of 2015 was $6.1 million compared with $5.3 million for the second quarter of 2014. The net loss for the first six months of 2015 was $12.0 million compared with $10.5 million for the first six months of 2014.Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) ended the last trading day at $4.63. Company weekly volatility is calculated as 8.14% and price to cash ratio as 2.95. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) showed a weekly performance of -3.94%.

On 4 August, Matson, Inc. (NYSE:MATX) has reported a net income of $9.9 million, or $0.23 per diluted share, for the second quarter of 2015, ending June 30.Matson, Inc. (NYSE:MATX) shares fell -0.79% in last trading session and ended the day at $42.70. MATX Gross Margin is 18.40% and its return on assets is 6.70%. Matson, Inc. (NYSE:MATX) quarterly performance is -0.81%.

Leave a Reply

Your email address will not be published. Required fields are marked *